Hypovitaminosis D and antiepileptic drugs
Review of evidence and recommendations
DOI:
https://doi.org/10.29193/RMU.35.3.5Abstract
Vitamin D is a fat-soluble vitamin, also considered a hormone that regulates mineral homeostasis and maintains the concentration of calcium within normal limits. Protects the integrity of the skeleton, modulates growth and cell differentiation. There is a wide distribution of its receptors throughout the body, especially at the level of bone, digestive system and kidney. In addition to its role in calcium homeostasis, vitamin D regulates other functions called extraosseous, with possible benefits, such as the regulation of the immune system, muscle function, cardiovascular and metabolic system. There is increasing evidence about vitamin D deficiency in the population. A review conducted in 2009 by the International Osteoporosis Foundation and National Osteoporosis Foundation was aimed at knowing the status of vitamin D in different regions of the world and identifying its determinants. It reported that hypovitaminosis D is widely spread across the six continents and is re-emerging as a global public health problem.
References
(1) Gobierno Vasco. Departamento de Salud. Vitamina D: evidencias y controversias. Bol INFAC 2012; 20(2):1-6. Disponible en: https://www.osakidetza.euskadi.eus/contenidos/informacion/cevime_infac/eu_miez/adjuntos/INFAC_Vol_20_n_2.pdf (Consulta: 2 de octubre de 2018).
(2) Bouillon R. Vitamin D and extraskeletal health. UpToDate 2017:1-22.
(3) Mithal A, Wahl DA, Bonjour JP, Burckhardt P, Dawson-Hughes B, Eisman JA, et al. Global vitamin D status and determinants of hypovitaminosis D. Osteoporos Int 2009;20(11):1807-20.
(4) Beerhost K, van der Krujis SJ, Verschuure P, Tan IY, Aldenkamp AP. Bone disease during chronic antiepileptic drug therapy: general versus specific risk factors. J Neurol Sci 2013; 331:19-25.
(5) Ganji V, Zhang X, Tangpricha V. Serum 25-hydroxivitamin D concentrations and prevalence estimates of hypovitaminosis D in the U.S. population based on assay-adjusted data. J Nutr 2012; 142(3):498-507.
(6) Puche R. Sobre la prevalencia de hipovitaminosis D en Argentina. Medicina (Buenos Aires) 2015; 75(3):183-6.
(7) Solá L, Leyún N, Díaz JC, González S, Sehabiague C, Parodi K, et al. Asociación de déficit de vitamina D y anemia en pacientes en hemodiálisis crónica. Rev Méd Urug 2014; 30(3):157-63.
(8) Gómez F, Bottaro S, Cóppola F , Tomasso G, Rocha V, Giménez C. Prevalencia del déficit de vitamina D en una población de embarazadas que se asisten en el Centro Hospitalario Pereira Rossell. Rev Méd Urug 2016; 32(2):87-97.
(9) Mendoza B, Ronco A. Estacionalidad de la vitamina D plasmática: su importancia en la clínica y en la salud. Rev Méd Urug 2016; 32(2):80-6.
(10) Tomita S, Ohnishi J, Nakano M, Ichikawa Y. The effect of anticonvulsant drugs on vitamin D3-activating cytochrome P-450-linked monooxygenase systems. J Steroid Biochem Mol Biol 1991; 39:479-85.
(11) Golden NH, Abrams SA. Optimizing bone health in children and adolescents. Pediatrics 2014; 134(4):e1229-43.
(12) Holick M, Binkley N, Bischoff-Ferrari H, Gordon C, Hanley D, Heaney R, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine society clinical practice guideline. J Clin Endocrinol Metab 2011; 96(7):1911-30.
(13) Estefanell C, Olivera R, Satriano R, Tanzi MN, Donangelo C, Salmenton M, et al. Pauta de vitamina D. Arch Pediatr Urug 2012; 83(1):31-4.
(1) 14.Krishnamoorty G, Nair R, Sundar U, Kini P, Shrivastava M. Early predisposition to osteomalacia in indian adults on phenytoin or valproate monotherapy and effective prophylaxis by simultaneous supplementation with calcium and 25-hydroxy vitamin D at recommended daily allowance dosage: a prospective study. Neurol India 2010; 58:213-9.
(14) Misra A, Aggarwal A, Singh O, Sharma S. Effect of carbamazepine therapy on vitamin D and parathormone in epileptic children. Pediatr Neurol 2010; 43(5):320-4.
(15) Teagarden D, Meador K, Loring D. Low vitamin D levels are common in patients with epilepsy. Epilepsy Res 2014; 108:1352-6.
(16) Borusiak P, Langer T, Heruth M, Karenfort M, Bettendorf U, Jenke A. Antiepileptics drugs and bone metabolism in children: data from 128 patients. J Child Neurol 2012; 28(2):176-83.
(17) Nicolaidou P, Georgouli H, Kotsalis H, Matsinos Y, Papadopoulou A, Fretzayas A, et al. Effects of anticonvulsant therapy on vitamin D status in children: prospective monitoring study. J Child Neurol 2006; 21(3):205-9.
(18) Saggese G, Vierucci F , Prodam F, Cardinale F, Cetin I, Chiappini E et al. Vitamin D in pediatric age: consensus of the Italian Pediatric Society and the Italian Society of Preventive and Social Pediatrics, jointly with the Italian Federation of Pediatricians. Italian J Pediatr 2018; 44:51.
(19) Wagner C, Greer F. Prevention of rickets and vitamin D deficiency in infants, children, and adolescents. Pediatrics 2008; 122(5):1142-52.
(20) Institute of Medicine. Dietary reference intakes for calcium and vitamin D. Washington DC: National Academies Press (US), 2011.
(21) Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton SK. The 2011 report on dietary reference intakes for calcium and vitamin D from the institute of medicine: what clinicians need to know. J Clin Endocrinol Metab 2011; 96(1):53-8.
(22) García Vadillo, J. Are calcium and vitamin D supplements for everyone?: Pro. Reumatol Clin 2011; 7(Sup.2):S34-9.
(23) Loza Santamaría E. Are calcium and vitamin D supplements for everyone?: Cons. Reumatol Clin 2011; 7(Sup.2):S40-5.
(24) García-Franco A, Navarro D, Corrochano E. Vitamina D: el traje nuevo del Rey Sol. Aten Primaria 2019; 51(2):57-8.
(25) Mengual Gil JM. Vitamina D por encima del año de vida, ¿es necesaria o está de moda? En: AEPap. Curso de Actualización Pediatría 2018. Madrid: Lúa Ediciones, 2018:17-30.
